SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU) - moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: JJINV12/12/2019 12:26:19 PM
1 Recommendation

Recommended By
patlawche11

  Read Replies (2) of 63324
 
Positive Trastuzumab Trial Data Offers Hope for Struggling Breast Cancer Patients
Published: Dec 12, 2019 By Mark Terry

AstraZeneca and Daiichi Sankyo presented positive data from their Phase II single-arm DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) in HER2-positive metastatic breast cancer patients who received two or more previous HER-2 targeted regimens. The objective response rate (ORR), which was the primary endpoint, was 60.9% with the drug alone

Safety and tolerability of the drug was consistent with that seen in the Phase I clinical trial. The most common Grade 3 or higher adverse events related to treatment were decreased neutrophil count, anemia, nausea, decreased white cell count, decreased lymphocyte count and fatigues. About 13.6% of patients had confirmed interstitial lung disease (ILD) related to treatment. Four deaths were associated with ILD. ILD is a broad group of disorders that cause scarring, or fibrosis, of the lungs.

biospace.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News